Burlingame, California, United States
Senior Medical Director at Genentech in oncology early clinical development. Post-graduate work was combining genome-scale CRISPR-Cas9 loss-of-function screening with large omics datasets to identify new targets in pediatric cancers in Kimberly Stegmaier's group at Dana-Farber Cancer Institute and Todd Golub's Cancer Data Science group at the Broad Institute. Former attending physician in pediatric hematology and oncology at Dana-Farber Cancer Institute and Boston Children's Hospital. Completed pediatric hematology and oncology fellowship at Dana-Farber Cancer Institute and Boston Children's Hospital. Completed pediatric residency at UCLA Medical Center which included Ronald Reagan UCLA Medical Center, Santa Monica UCLA Medical Center, Olive View UCLA Medical Center and Cedars Sinai Medical Center. Graduate work was in malaria research using bioinformatic techniques including genomic microarray and sequence analysis. Using whole-genome methods to elucidate mechanisms of drug resistance and study populations of malaria parasites. Specialties: Pediatrics, oncology, computational biology, functional genomics, target identification, data science, sequence analysis, early phase clinical trials.
Early Clinical Development Oncology
Early Clinical Development Oncology
Early Clinical Development Oncology
Post-graduate work was combining genome-scale CRISPR-Cas9 loss-of-function screening with large omics datasets to identify new targets in pediatric cancers in Kimberly Stegmaier's group at Dana-Farber Cancer Institute and Todd Golub's Cancer Data Science group at the Broad Institute.
Post-graduate work was combining genome-scale CRISPR-Cas9 loss-of-function screening with large omics datasets to identify new targets in pediatric cancers in Kimberly Stegmaier's group at Dana-Farber Cancer Institute and Todd Golub's Cancer Data Science group at the Broad Institute.
Post-graduate work was combining genome-scale CRISPR-Cas9 loss-of-function screening with large omics datasets to identify new targets in pediatric cancers in Kimberly Stegmaier's group at Dana-Farber Cancer Institute and Todd Golub's Cancer Data Science group at the Broad Institute.